Market Overview

Ambys Medicines Launches with $140 Million to Pioneer Regenerative Medicine Therapies for Serious Liver Diseases


Ambys Medicines, a company founded to capitalize on advances in liver
biology and regenerative medicines to develop therapies for serious
liver diseases, launched today with a $60 million Series A financing
funded by Third Rock Ventures and Takeda. As part of the launch, Ambys
also announced today a strategic partnership with Takeda bringing total
committed funding at launch to $140 million.

Ambys Medicines is pursuing multiple strategies to develop innovative
new medicines for patients suffering from chronic liver diseases,
including cell therapy for hepatocyte transplantation, gene therapy for
liver regeneration, and drug therapy to replace lost protein function.

"With the launch of Ambys, we are seizing the opportunity to radically
reshape the way in which serious liver diseases are treated," said
Jeffrey Tong, Ph.D., chief executive officer of Ambys Medicines and
venture partner with Third Rock Ventures. "Major advances in the fields
of gene and cell therapy and gain-of-function drug therapies, coupled
with deeper understanding of liver biology, create the potential to
develop drug therapies that can now restore or replace natural liver

The Ambys team includes recognized leaders in regenerative medicine,
drug discovery, translational medicine and company-building. Company
leaders include Jeffrey Tong, Ph.D., interim Chief Executive Officer;
Michael Holmes, Ph.D., Chief Scientific Officer; Jeffrey Finer, M.D.,
Ph.D., interim Chief Technology Officer; Glenn Pierce, M.D., Ph.D.,
interim Chief Medical Officer; and Stanley Hollenbach, Senior Vice
President of Pharmacology.

Scientific co-founders of Ambys include world-renowned experts in liver
disease, cell and gene therapy, and small molecules that can replace
protein function:

  • Martin Burke, M.D., Ph.D. is Professor of Chemistry at the
    University of Illinois at Urbana-Champaign
  • Markus Grompe, M.D. is the Ray Hickey Professor and Director of
    the Papé Family Pediatric Research Institute at Oregon Health &
    Science University, and the Director of the Oregon Stem Cell Center
  • Juan Carlos Izpisua Belmonte, Ph.D. is Professor and Roger
    Guillemin Chair of the Gene Expression Laboratories at the Salk
    Institute for Biological Studies
  • Holger Willenbring, M.D., Ph.D. is Professor of Surgery at the
    University of California, San Francisco

"By assembling a group of world-renowned scientific co-founders and
experienced company leadership, Ambys is tapping into leading-edge
approaches to develop therapeutics for liver disease by restoring or
replacing missing function," said Charles Homcy, M.D., partner at Third
Rock and board member of Ambys.

"This is a unique confluence in time to bring together multiple
regenerative approaches to tackle very serious unmet needs remaining in
chronic liver disease today," said Asit Parikh, M.D., Ph.D., Head,
Gastroenterology Therapeutic Area Unit at Takeda and board member of
Ambys. "We are excited to be joining Ambys at the launch of this
exciting company."

About Ambys Medicines

Ambys Medicines is a biotechnology company focused on discovering and
developing transformative therapies for people with advanced liver
disease. Founded by world-renowned experts in liver disease and
regenerative medicine, Ambys is pioneering the application of novel
modalities including cell and gene therapy, and gain-of-function drug
therapy, to meet the urgent need for treatments that have potential to
restore liver function and prevent the progression to liver failure
across multiple liver diseases that are untreatable or poorly treated
today. Ambys was launched in 2018 by Third Rock Ventures and Takeda
Pharmaceuticals, and is headquartered in Redwood City, Calif. For more
information, please visit

About Third Rock Ventures

Third Rock Ventures is a leading healthcare venture firm focused on
disruptive areas of science and medicine to discover, launch and build
companies that make a dramatic difference in people's lives. By
combining our team's scientific vision, strategic leadership,
operational expertise and innovative deal-making capabilities, we
nurture bold ideas that translate into successful business enterprises.
Recognizing that the best way to create value for our investors is to
create value for patients, our companies are built on a solid foundation
of science, medicine, people and business strategy. For more
information, please visit

View Comments and Join the Discussion!